Skip to content
Back to meeting Original
Roberto Borea, MD· @RobertoBoreaMD · X·· 2 days agoScore70

ASTRIDE

Body

Congrats to @drgandara on presenting ASTRIDE at #ESMO26!
Randomized bridging trial in US pts with ES-SCLC: serplulimab vs atezolizumab + chemo
-mOS 12.4 vs 10.2 mo (HR 0.82)
-24-mo OS 32.2% vs 17.6%
-Similar safety
Supports ASTRUM-005 findings in US pts
@myESMO @isliquidbiopsy

27 views · 0 likes · 1 repost · 0 replies

Conference abstracts

Source: Roberto Borea, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.